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In Brief
Varin et al. report that DPP4 activity and sDPP4 protein differentially regulate glucose homeostasis and inflammation, and that this regulation is dependent upon the cellular source of DPP4. Remarkably, DPP4 inhibitors robustly induce plasma levels of sDPP4, revealing divergence of glucoregulatory DPP4 enzymatic activity versus levels of immuno-modulatory sDPP4.
SUMMARY
Dipeptidyl peptidase-4 (DPP-4) controls glucose homeostasis through enzymatic termination of incretin action. We report that plasma DPP-4 activity correlates with body weight and fat mass, but not glucose control, in mice. Genetic disruption of adipocyte Dpp4 expression reduced plasma DPP-4 activity in older mice but did not perturb incretin levels or glucose homeostasis. Knockdown of hepatocyte Dpp4 completely abrogated the obesity-associated increase in plasma DPP-4 activity, reduced liver cytokine expression, and partially attenuated inflammation in adipose tissue without changes in incretin levels or glucose homeostasis. In contrast, circulating levels of soluble DPP4 (sDPP4) were dissociated from inflammation in mice with endothelial-selective or global genetic inactivation of Dpp4. Remarkably, inhibition of DPP-4 enzymatic activity upregulated circulating levels of sDPP4 originating from endothelial or hematopoietic cells without inducing systemic or localized inflammation. Collectively, these findings reveal unexpected complexity in regulation of soluble versus enzymatic DPP-4 and control of inflammation and glucose homeostasis.
INTRODUCTION
Type 2 diabetes mellitus (T2D) is a metabolic disorder characterized by hyperglycemia, resulting from a combination of islet cell dysfunction (insufficient insulin and excess glucagon secretion) and insulin resistance. Incretin hormones, principally glucagonlike peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to control of islet function. Their bioactivity is regulated by the enzymatic activity of dipeptidyl peptidase-4 (DPP-4), a widely expressed serine protease (Deacon, 2004; Mulvihill and Drucker, 2014; Omar and Ahren, 2014) . Plasma DPP-4 activity increases with obesity, and this increase has been postulated to contribute to reduced incretin activity in the setting of obesity and insulin resistance (Ahmed et al., 2017) .
DPP-4 also modulates local and systemic inflammation through cleavage of immunoregulatory DPP-4 substrates (Donath and Shoelson, 2011; Mulvihill and Drucker, 2014; Waumans et al., 2015) . Notably, systemic reduction of DPP-4 activity achieved through administration of highly selective DPP-4 inhibitors reduces glycaemia in subjects with T2D (Deacon, 2018; Mulvihill and Drucker, 2014; Sandoval and D'Alessio, 2015; Vella, 2012) . DPP-4 inhibitors also reduce inflammation in preclinical studies and in human subjects with T2D (Makdissi et al., 2012; Mulvihill and Drucker, 2014; Satoh-Asahara et al., 2013; Zhuge et al., 2016) . Nevertheless, the precise cell types and tissues critical for linking DPP-4 activity to the control of (1) glucose homeostasis and (2) inflammation are complex and remain incompletely understood (Mulvihill et al., 2017; Omar and Ahren, 2014) .
Several studies have proposed that circulating soluble DPP-4 (sDPP4) is released from adipose tissue and acts as a pro-inflammatory adipokine, linking expansion of adipose tissue with increased inflammation, insulin resistance, and metabolic syndrome (Chowdhury et al., 2016; Lamers et al., 2011; Sell et al., 2013; Zillessen et al., 2016) . Indeed, increased plasma DPP-4 activity accompanies adipose tissue expansion in humans, rats, and mice (Kirino et al., 2009; Lamers et al., 2011; Mulvihill et al., 2017; Zhuge et al., 2016) . Moreover, small interfering RNA-mediated depletion of Dpp4 from human primary adipocytes improved adipocyte insulin sensitivity (Rohrborn et al., 2016) , whereas treatment with sDPP4 directly activated inflammatory signaling pathways ex vivo (Lee et al., 2016; Romacho et al., 2016) .
A complementary body of evidence supports a role for hepatic Dpp4 in the control of metabolism. Liver DPP4 expression is elevated in subjects with hepatic fat accumulation (Miyazaki et al., 2012) , and hepatic Dpp4 expression correlates with the Echo-MRI (B, E, and H) , and the correlation between plasma DPP-4 activity and fat mass (C, F, and I) in control mice (8-12 weeks old) fed a regular chow (RC) diet, or after 12 weeks of high-fat diet (HFD) (45% kcal from fat, 24-or 32week-old mice) (A-C) (n = 11-30/group), or in 18-week-old WT mice fed a control diet (CD) or 40% fat, 20% fructose, 2% cholesterol diet (HFHC) for 12 weeks (D-F) (n = 9/group), or in 6-or 12-week-old db/+ and db/db mice (G-I) (n = 5/group) fed RC. (J-L) Plasma DPP-4 activity (J), non-fasted blood glucose (K), and the correlation between both (L) in WT mice fed the HFD for 10-20 weeks, and then intraperitoneally (i.p.) injected twice a day with 5 nmol/kg of Ex-4 (10:00 and 18:00 h) or vehicle for 7 days (n = 5/group). (M-R) Relative Dpp4 mRNA level (M and O) and DPP-4 activity (N and P) in the indicated tissues in 24-week-old male mice fed an RC diet (M and N) or fed the HFD for 12 weeks (O and P) (n = 7/group). (Q) DPP-4 immunostaining in inguinal white adipose tissue (iWAT) and epididymal WAT (eWAT) of 24-week-old WT male mice maintained on an RC diet.
(legend continued on next page) degree of hepatosteatosis, insulin resistance, and plasma DPP-4 activity (Balaban et al., 2007; Baumeier et al., 2017a) . Moreover, transgenic mice overexpressing Dpp4 in the liver exhibit increased liver and adipose tissue inflammation and insulin resistance (Baumeier et al., 2017b) . Ghorpade et al. (2018) suggested that liver DPP-4 acts as a hepatokine by demonstrating a role for hepatocyte-derived sDPP4 in control of adipose tissue inflammation, insulin resistance, and glucose homeostasis. Accordingly, we have now assessed the metabolic importance of DPP-4 enzymatic activity and circulating levels of DPP4 through generation and analysis of mice with loss of Dpp4 in multiple tissues and cell types. Adipocyte Dpp4 was expressed at very low levels and contributed modestly to plasma DPP-4 activity, and selective loss of adipocyte Dpp4 did not meaningfully impact concentrations of active incretin hormones or glucose homeostasis. In contrast, we find that hepatocyte-derived DPP-4 is the source of obesity-associated increases in plasma DPP-4 activity. However, while hepatocyte-derived DPP-4 controls hepatic and adipose tissue inflammation, it is dispensable for systemic glucose control. Interestingly, the reduction in local inflammation following selective targeting of hepatocyte Dpp4 is not recapitulated in two different mouse models presenting partial or total reduction in plasma DPP4 activity and circulating sDPP4. Finally, we reveal a feedback loop linking systemic inhibition of DPP-4 enzymatic activity to upregulation of circulating protein levels of DPP4 (sDPP4). These findings reveal dissociation of circulating levels of sDPP4, DPP-4 enzyme activity, and control of obesity-associated inflammatory signals in the liver and adipose tissue.
RESULTS
Plasma DPP-4 Activity Increases with Age and Obesity
Plasma DPP-4 activity increased with age and high-fat diet (HFD) feeding ( Figure 1A) and correlated with increased fat mass or increased body weight ( Figures 1B, 1C , S1A, and S1B). Plasma DPP-4 activity and fat mass or body weight were also increased and correlated in mice fed a high-fat, high-fructose, high-cholesterol (HFHC) diet ( Figures 1D-1F , S1C, and S1D) and in regular chow (RC)-fed db/db mice ( Figures 1G-1I , S1E, and S1F). In contrast, plasma DPP-4 activity did not correlate with fluctuations in glucose levels in HFD-fed mice treated with or without the GLP-1R agonist exendin-4 (Ex-4, 5 nmol/kg, twice daily) . Hence plasma DPP-4 activity increases with weight gain and correlates with adipose tissue mass.
DPP-4 Expression and Activity in Adipose Tissue
As increased levels of plasma DPP-4 have been proposed to arise from adipose tissue, reflecting its role as a putative adipo-kine (Lamers et al., 2011; Sell et al., 2013; Zillessen et al., 2016) , we examined the relative tissue expression of Dpp4 mRNA and DPP-4 activity after RC or HFD feeding for 12 weeks (Figures S1G-S1I). Levels of Dpp4 mRNA transcripts were much higher in ileum and jejunum compared with levels in white adipose tissue (WAT) depots in RC-fed mice ( Figure 1M ). In contrast, DPP-4 activity was greater in liver relative to gut tissues and extremely low in WAT depots ( Figure 1N ). Similar results were detected after 12 weeks of HFD feeding ( Figures 1O and 1P) ; levels of Dpp4 mRNA ( Figure 1O ) and DPP-4 activity ( Figure 1P ) remained 25-to 70-fold lower in WAT depots, relative to levels in gut, liver, and kidney.
Although DPP-4 expression has been extensively characterized in adipocytes (Lamers et al., 2011; Lessard et al., 2015) , after isolating adipocytes from stromal vascular fractions (SVFs) (Figures S1J and S1K) we localized DPP-4 protein and Dpp4 mRNA predominantly to the non-adipocyte cell population within adipose tissue (Figures 1Q and 1R) . Dpp4 mRNA transcripts were more abundant in the SVF from inguinal WAT (iWAT), epididymal WAT (eWAT), retroperitoneal WAT (rWAT), and interscapular brown adipose tissue of RC-and HFD-fed mice ( Figures  1R-1T ). To determine whether Dpp4 expression was modulated during adipocyte differentiation, we assessed Dpp4 mRNA expression throughout differentiation in 3T3-L1 cells (Figures 1U and S1L) . Dpp4 expression was unchanged throughout the 8-day process despite significant increases in well-described markers of differentiation such as lipoprotein lipase (Lpl), peroxisome proliferator activated receptor (Ppar)g, fatty acid binding protein 4 (Fabp4), adiponectin (Adipoq), and CCAAT/enhancerbinding protein a (Cebpa) ( Figure S1L ); notably, Dpp4 expression was 200-to 3,000-fold less abundant than three related members of the same enzyme family (Dpp8, Dpp9, and Fap) ( Figure 1U ).
Genetic Targeting of Adipocyte Dpp4
Despite low levels of adipocyte Dpp4 expression in fat from RCand HFD-fed mice, we could not rule out a metabolic role for adipocyte DPP-4 under conditions of weight gain and expansion of adipocyte tissue mass. Accordingly, we crossed Dpp4 Flox/Flox mice (Mulvihill et al., 2017) with mice expressing Cre recombinase under control of the adiponectin promoter to generate Dpp4 AdipoÀ/À mice (Lee et al., 2013) . Analysis of genomic DNA (gDNA) from Dpp4 AdipoÀ/À mice revealed selective recombination of the Dpp4 gene in DNA from WAT adipocytes (Figures S2A and S2B) . Nevertheless, body weight, fat mass, WAT depot, and liver mass were not different ( Figures S2C-S2E ) and plasma DPP-4 activity and DPP-4 protein concentrations, fasting glucose, glucose tolerance, and plasma levels of insulin and intact GLP-1 were similar in Dpp4 Adipo+/+ versus Dpp4 AdipoÀ/À mice on RC and after 20 weeks of HFD feeding ( Figures S2F-S2I ). Moreover, the DPP-4 inhibitor sitagliptin improved glucose tolerance and augmented glucose-stimulated levels of insulin and GLP-1 to a similar extent after RC (Figures S2J and S2K) or HFD feeding (Figures S2L and S2M) in Dpp4 Adipo+/+ versus Dpp4 AdipoÀ/À mice. Hence, adipocytederived DPP-4 is expressed at very low levels, and is not essential for basal or diet-induced obesity-associated increases in plasma DPP-4 activity, incretin degradation, glucose homeostasis, or the glucoregulatory response to sitagliptin in adult mice up to 32 weeks of age.
The Contribution of Adipocyte-Derived DPP-4 to Metabolic Phenotypes in Older Mice
To assess whether adipocyte DPP-4 expression increases with age, we studied 1-year-old Dpp4 AdipoÀ/À HFHC-fed mice. Dpp4 mRNA and DPP-4 activity remained relatively higher in liver versus WAT from older wild-type (WT) and Dpp4 AdipoÀ/À mice (Figures 2A and 2B) , and levels of Dpp4 mRNA and DPP-4 activ-ity were not different in whole adipose tissue depots from older Dpp4 AdipoÀ/À versus Dpp4 Adipo+/+ mice (Figures 2A and 2B ). Nevertheless, levels of Dpp4 mRNA and DPP-4 activity were reduced in isolated adipocyte fractions (but not the SVF) from iWAT, eWAT, and rWAT of older Dpp4 AdipoÀ/À mice (Figures 2C and 2D) . Furthermore, plasma DPP-4 activity and circulating levels of sDPP4 were reduced and levels of active GIP, but not GLP-1, were increased in older Dpp4 AdipoÀ/À mice (Figures 2E and 2F) . However, oral glucose tolerance, and plasma levels of glucose-stimulated insulin, active GLP-1, and GIP were unchanged (Figures 2G and 2H) . Insulin tolerance was improved ( Figure 2I ), in the context of a slight reduction in body weight (Figure 2J) . Dpp4 AdipoÀ/À mice also exhibited reduced hepatic levels of mRNA and/or protein for interleukin-1b (IL-1b), IL-6, tumor necrosis factor alpha (TNF-a), F4/80 (Adgre1), and transforming growth factor b1, and an increase in interferon-g (IFN-g) protein and mRNA levels of the anti-inflammatory M2 macrophage marker Mgl2 (Figures 2K, 2L , S3A, and S3B). In contrast, levels of cytokine mRNA transcripts and protein concentrations were not different in eWAT and iWAT, except for an increase in CXCL1 in eWAT and plasma ( Figures S3C-S3G ). Taken together, adipocyte-derived DPP-4 contributes to the pool of circulating sDPP4 and DPP-4 activity in older, obese HFHC-fed mice, yet its elimination is not associated with major impairment in the control of incretin levels or glucose homeostasis.
Hepatocyte DPP-4 Contributes to Plasma DPP-4 Activity, but Not to Glucose Control As hepatocyte-derived DPP-4 has been proposed to function as a hepatokine (Baumeier et al., 2017b; Ghorpade et al., 2018) , we assessed whether endogenous hepatocyte-derived DPP-4 contributes to the circulating pool of DPP-4 activity and control of glucose homeostasis. We used an adeno-associated virus (AAV) expressing Cre recombinase under the control of the thyroxine-binding globulin (TBG) promotor (Sun et al., 2012) to generate Dpp4 HepÀ/À mice. Injection of AAV-TBG-Cre recombined gDNA in liver, selectively in hepatocytes ( Figure 3A) , and markedly reduced total hepatic Dpp4 expression and DPP-4 activity (Figures 3B and 3C) . A near complete elimination of Dpp4 expression was detected specifically in hepatocytes ( Figure 3D ), and not in the non-parenchymal cell fraction ( Figures 3D, S4A , and S4B). In contrast, no recombination of the Dpp4 gene, reduction of Dpp4 expression, or DPP-4 activity was detected in kidney, spleen, lung, or jejunum in RC-fed Dpp4 HepÀ/À mice ( Figures S4D-S4F ), or in iWAT or eWAT after RC or HFHC feeding ( Figure S4G ) in Dpp4 HepÀ/À mice. RC-fed Dpp4 HepÀ/À mice ( Figure S4I ) exhibited a small reduction in plasma levels of DPP-4 activity and protein (sDPP4) ( Figure 3E ). However, glucose tolerance and plasma levels of insulin, active GLP-1, and GIP were not different before and after glucose challenge in Dpp4 Hep+/+ mice versus Dpp4 HepÀ/À mice (Figures 3F and 3G) . Hepatic and plasma triglycerides and plasma non-esterified fatty acids were not different in Dpp4 Hep+/+ versus Dpp4 HepÀ/À mice (Figures S4K and S4L) . Moreover, hepatocyte-derived DPP-4 was not required for the glucoregulatory response to the DPP-4 inhibitor sitagliptin, which improved glucose tolerance and increased plasma levels of insulin, active GLP-1, and active GIP to a similar extent in Dpp4 Hep+/+ versus Dpp4 HepÀ/À mice ( Figures 3H-3K ).
Increased Plasma DPP-4 Activity in HFHC-Fed Mice Is Derived from Hepatocytes
We next examined the contribution of hepatocyte DPP-4 to plasma DPP-4 activity and glucose homeostasis after HFHC feeding for 10 weeks ( Figure S4J ), a diet shown to increase circulating DPP-4 activity ( Figure 1D ) and induce metabolic inflammation in multiple tissues, including the liver (Hsieh et al., 2016) . Liver DPP-4 activity was markedly reduced and the increase in plasma DPP-4 activity associated with HFHC feeding was totally abolished in HFHC-fed Dpp4 HepÀ/À mice ( Figures 3L and 3M ). Nevertheless, circulating levels of sDPP4 in Dpp4 HepÀ/À mice were not different from Dpp4 Hep+/+ mice ( Figure 3M ). Fasting plasma levels of active GLP-1 were increased and GIP trended higher in fasted Dpp4 HepÀ/À mice ( Figures 3N and 3O ). However, glucose tolerance and circulating levels of glucose-stimulated intact GLP-1 and GIP were similar in Dpp4 HepÀ/À versus Dpp4 Hep+/+ mice ( Figures 3P-3Q ). Although body weight was not different ( Figure 3R ), plasma levels of glucose-stimulated insulin were reduced and insulin sensitivity was modestly increased, reflecting delayed recovery of glycemia, in HFHCfed Dpp4 HepÀ/À mice ( Figures 3S and 3T ).
Hepatocyte-Derived DPP-4 Influences Inflammation in the Liver and Adipose Tissue
As the reduction of sDPP4 and DPP-4 activity has been linked to reduced local tissue and systemic inflammation (Ghorpade et al., 2018; Mulvihill and Drucker, 2014) , we assessed cytokine mRNA levels and protein concentrations in the liver of RC-and HFHCfed Dpp4 HepÀ/À mice. Intriguingly, hepatic levels of Ccl2, Adgre1, Il2, and Acta2 mRNAs were reduced, and Tnfa trended lower in HFHC-fed Dpp4 HepÀ/À mice ( Figures 4A and S5A ). Levels of the M2 anti-inflammatory macrophage markers Mgl2 and Arg1 were unchanged ( Figure S5A ), and the mRNA encoding the DPP-4 binding protein Ada was increased ( Figure 4A ). Moreover, hepatic cytokine protein concentrations of CXCL1, 1L-1b, IL-2, IL-5, and IL-6 were lower in HFHC-fed Dpp4 HepÀ/À mice ( Figures 4B and S5C ). Furthermore, mRNA levels of Adgre1 (F4/80), Il1b, Il2, Il12b, and Ccl2 were lower, and protein levels of TNF-a and IL-1b were reduced in eWAT from Dpp4 HepÀ/À mice ( Figures 4C, 4D , S5B, and S5D). The increase in Adgre1 mRNA expression in adipose tissue from HFHC-fed control mice versus Dpp4 HepÀ/À mice corresponded with results of (F and G) Glucose excursion, AUC, plasma insulin (F), and plasma levels of active incretin hormones (G) before and 15 min after glucose gavage during oGTT (5 hr fast, 2 g/kg glucose) in Dpp4 Hep+/+ and Dpp4 HepÀ/mice fed an RC diet (7-12 days after AAV injection) (n = 13/group). (H-K) Glucose excursion, AUC, plasma insulin (H and J), and plasma active incretin hormone levels (I and K) before and 15 min after glucose gavage, in response to water (blue) (or acute inhibition of DPP-4 (10 mg/kg sitagliptin, 1 mg/mL solution, given by gavage 30 min before glucose) in Dpp4 Hep+/+ and Dpp4 HepÀ/mice under RC diet conditions (n = 13/group). (L-T) Liver DPP-4 activity (L), plasma DPP-4 activity, and plasma DPP4 protein concentrations (sDPP4) in mice fed RC or HFHC diets for 10 weeks prior to AAV injection, and 4 weeks following AAV injection (HFHC + virus) (M), 5-hr-fasted plasma levels of active GLP-1 and active GIP (N and O), glucose excursion and AUC (P) and incretin hormones (Q) during OGTT, body weights before and after 10 and 14 weeks of HFHC diet (R), insulin during OGTT (S), glucose excursion during an insulin tolerance test (1 U/kg insulin) (T) 3 weeks after AAV injection, and in HFHC diet-fed Dpp4 Hep+/+ and Dpp4 HepÀ/mice (n = 10-12/group). Data are presented as the means ± SEM. *p % 0.05, **p % 0.01, ***p % 0.001 using t test (B, C, E, L, N-P, and T), one-way-ANOVA (D, M, and R), or a two-way ANOVA (F-K, Q, and S). See also Figure S4 . immunostaining showing a reduction in crown-like structures in eWAT of Dpp4 HepÀ/À mice ( Figure 4F ). Selective reduction of hepatocyte-derived DPP-4 also reduced levels of plasma IL-6 ( Figure 4E ), without affecting plasma levels of IL-2, IL-5, IL-10, IFN-g, IL-1b, TNF-a, and CXCL1 ( Figure S5E ).
Reduction of sDPP4 and DPP-4 Activity in Dpp4 EC-/-Mice Does Not Reduce Markers of Tissue or Systemic Inflammation As endothelial and hematopoietic cells also contribute to the circulating pool of plasma DPP-4 activity (Mulvihill et al., 2017) , we assessed local and systemic inflammation in RC-and HFDfed Dpp4 ECÀ/À mice. Consistent with the reduction of plasma DPP-4 activity ( Figure 5A ) (Mulvihill et al., 2017) , circulating levels of sDPP4 were substantially reduced in Dpp4 ECÀ/À mice (Figure 5A) . Nevertheless, insulin tolerance was not different under RC conditions and was actually impaired in HFD-fed Dpp4 ECÀ/À compared with Dpp4 EC+/+ mice ( Figures 5B and 5C ). Despite lower circulating levels of sDPP4, multiple markers of inflammation were not different in liver, WAT, or plasma from RC-and HFD-fed Dpp4 ECÀ/À mice compared with their littermate controls ( Figures 5D and S6A-S6F) . Surprisingly, TNF-a was increased in eWAT and plasma from HFD-fed Dpp4 ECÀ/À mice (Figures 5E and 5F). With prolonged HFD feeding, plasma DPP-4 activity was no longer reduced; however, circulating levels of sDPP4 remained substantially lower in Dpp4 ECÀ/À mice ( Figure 5G ). Collectively, these findings dissociate reductions in circulating levels of sDPP4 from corresponding changes in tissue and systemic inflammation and plasma DPP-4 activity in vivo.
Complete Elimination of DPP-4 Expression Does Not Reduce Cytokine Expression in HFD-Fed Mice
To further examine the importance of circulating sDPP4 for hepatic and WAT inflammation, we studied Dpp4 À/À mice with whole-body inactivation of the Dpp4 gene (Marguet et al., 2000; Mulvihill et al., 2017) . Plasma DPP-4 activity and circulating sDPP4 were markedly diminished or undetectable, respectively, in younger RC-and HFD-fed Dpp4 À/À mice (Figure 5H) . Insulin sensitivity was improved ( Figure 5I ), and the expression of a number of cytokines was reduced in liver, eWAT, and plasma from RC-fed Dpp4 À/À mice ( Figures 5J-5L and S6G-S6I). In contrast, despite the complete elimination of circulating sDPP4, insulin sensitivity was not improved, and pro-inflammatory cytokine expression was not reduced in WAT, liver, or plasma from HFD-fed Dpp4 À/À mice (Figures 5M-5P and S6J-S6L).
Dissociation of Circulating Levels of sDPP4, DPP-4 Activity, and Markers of Inflammation
To further understand the relationship between circulating DPP-4 activity and inflammation, we analyzed markers of tissue and systemic inflammation in HFHC-fed mice treated with the highly selective DPP-4 inhibitor, MK-0626 (Edmondson et al., 2006; Mulvihill et al., 2016) . Consistent with previous findings, plasma and tissue DPP-4 activity was markedly suppressed, and plasma active GLP-1 levels were increased in MK-0626treated mice ( Figures 6A-6D ). Unexpectedly, HFHC-fed mice treated with MK-0626 exhibited a marked $4-fold increase in levels of circulating sDPP4 ( Figure 6E ). Nevertheless, tissue and plasma cytokine levels were not different in HFHC-fed mice with profound suppression of DPP-4 activity, despite elevated levels of sDPP4 ( Figures 6F-6H ).
Given the emerging role of sDPP4 as a pro-inflammatory mediator (Ghorpade et al., 2018; Zhong et al., 2013) , and the surprising increase in sDPP4 levels in mice with robust suppression of DPP-4 enzyme activity ( Figures 6A and 6E) , we analyzed circulating sDPP4 levels in several additional groups of mice on different diets, treated with and without structurally distinct DPP-4 inhibitors. Plasma DPP-4 activity was suppressed, whereas circulating levels of sDPP4 were consistently increased several-fold in all cohorts of mice treated with MK-0626 for 2-14 weeks ( Figures 6I-6L ). Furthermore, systemic DPP-4 inhibition, associated with an increase in ventricle inflammation and fibrosis markers (as described in Mulvihill et al., 2016) , was also associated with increased circulating levels of sDPP4 in HFD-fed diabetic mice exposed to sham or transaortic constriction surgery ( Figure 6M ). Importantly, upregulation of circulating levels of sDPP4 was also observed within several days following administration of two clinically approved DPP-4 inhibitors in the drinking water, sitagliptin and linagliptin ( Figures 6N-6O) .
To determine the cellular origin of sDPP4 induced by treatment of mice with DPP-4 inhibitors, we analyzed Dpp4 HepÀ/À , Dpp4 AdipoÀ/À , Dpp4 GutÀ/À and Dpp4 ECÀ/À mice after HFHC feeding and continuous administration of a DPP4i (MK-0626) for 5 weeks. MK-0626 reduced plasma DPP-4 activity in all groups of mice (left panels, Figures 7A-7D ). Plasma levels of sDPP4 were increased following MK-0626 administration in Dpp4 HepÀ/À , Dpp4 AdipoÀ/À , and Dpp4 GutÀ/À mice ( Figures 7A-7C , right panels). In contrast, MK-0626 suppressed DPP-4 enzymatic activity but failed to robustly upregulate levels of circulating sDPP4 in Dpp4 ECÀ/À mice ( Figure 7D ). These findings indicate that DPP-4 inhibition requires Dpp4 expression in Tie2 + cells of hematopoietic or endothelial lineage for maximal upregulation of circulating levels of sDPP4. Collectively, these experiments identify unexpectedly complex relationships between plasma DPP-4 enzyme activity, circulating levels of sDPP4, and the control of inflammation and glucose homeostasis ( Figures 7E and S7 ).
DISCUSSION
Clinical reports associating increased plasma levels of DPP-4 and circulating DPP-4 activity with weight gain and insulin resistance (Mulvihill and Drucker, 2014; Sell et al., 2013) prompted us to determine the source and metabolic relevance of obesity-associated alterations in DPP-4 expression and activity. Despite studies implicating DPP-4 as an adipokine (Lamers et al., 2011; Sell et al., 2013) , Dpp4 expression was relatively low in WAT depots and most abundant within cells of the SVF, as described previously (Shin et al., 2017; Zhong et al., 2013; Zhuge et al., 2016) . Moreover, Dpp4 expression did not increase to a meaningful extent in WAT from HFD-fed mice. Analysis of Dpp4 AdipoÀ/À mice up to 32 weeks of age did not reveal reduction in basal or HFD-stimulated plasma DPP-4 activity, or any apparent changes in plasma levels of intact incretin hormones or glucose homeostasis. Furthermore, Dpp4 expression was not induced during an 8-day differentiation of mouse 3T3-L1 fibroblasts to mature adipocytes. One-year-old HFHC-fed Dpp4 AdipoÀ/À mice exhibited a selective reduction in WAT Dpp4 expression and DPP-4 activity and reduced plasma DPP-4 activity. However, these findings were not accompanied by evidence for compelling alterations in glucose homeostasis. Hence, adipocyte DPP-4 activity is not critical for the control of incretin activity and glucose metabolism in mice.
In contrast, selective genetic reduction of hepatocyte-derived Dpp4 expression completely attenuated the increase of plasma DPP-4 activity in mice with diet-induced obesity. Intriguingly, loss of hepatocyte DPP-4 led to an increase in fasting levels of active GLP-1, and active GIP trended higher. Nevertheless, this reduction in hepatocyte and plasma DPP-4 activity was not associated with increased levels of intact incretin hormones after glucose administration, nor any improvements in glucose tolerance. These findings are consistent with our recent observations that reduction of DPP-4 in different cellular compartments, such as endothelial cells, hematopoietic cells, and enterocytes, produces differential effects on incretin degradation, plasma DPP-4 activity, and potentiation of the enteroendocrine axis (Mulvihill et al., 2017) . Hence, our current findings extend the concept of compartment-specific DPP-4 expression in the control of incretin hormone cleavage by establishing a limited role for hepatocyte DPP-4 in the regulation of bioactive GLP-1 selectively in the fasting state.
A number of intriguing findings were noted in mice with attenuation of hepatocyte Dpp4 expression. First, levels of several cytokine mRNA transcripts and proteins were lower in the liver and adipose tissue of mice with reduced hepatocyte Dpp4 expression. Importantly, robust systemic catalytic inhibition of DPP-4 activity (including plasma and liver) of HFHC-fed mice did not recapitulate the anti-inflammatory phenotype(s) observed in Dpp4 HepÀ/À mice. These findings are consistent with recent studies linking hepatocyte-derived sDPP4, independent of its catalytic activity, to the control of adipocyte inflammation (Dong et al., 1996; Ghorpade et al., 2018; Ishii et al., 2001; Zhong et al., 2013) .
Although anti-inflammatory actions have been described following inhibition of DPP-4 activity in multiple cell types and tissues, the literature contains contradictory reports as to whether the anti-inflammatory actions of DPP-4 are dependent on (Lee et al., 2016; Shinjo et al., 2015; Zhuge et al., 2016) , or independent (Ghorpade et al., 2018; Zhong et al., 2013) of, its enzymatic catalytic activity. Notably, enhanced expression of hepatic DPP-4 and levels of circulating DPP-4 activity and protein correlate with features of steatohepatitis in preclinical and clinical studies (Baumeier et al., 2017a (Baumeier et al., , 2017b Williams et al., 2015) . Nevertheless, systemic inhibition of DPP-4 catalytic activity with sitagliptin did not attenuate the extent of biopsy-proven steatohepatitis or fibrosis in a randomized control trial in human subjects (Joy et al., 2017) . These latter findings are consistent with lack of change in urinary cytokine levels following 1 month of daily sitagliptin administration in humans with T2D (Lovshin et al., 2017) .
The demonstration that sDPP4 derived from high-fat-fed mouse hepatocytes augments pro-inflammatory activity in visceral adipose tissue via macrophage caveolin-1 (Ghorpade et al., 2018) prompted us to re-assess the correlation between sDPP4 expression and inflammation. Although tissue and circulating markers of inflammation were reduced in RC-fed Dpp4 À/À mice, inflammation was not reduced in tissues from HFD-fed Dpp4 À/À mice despite complete loss of sDPP4. Furthermore, RC-or HFD-fed Dpp4 ECÀ/À mice exhibited substantially lower levels of circulating sDPP4, yet no reduction in levels of pro-inflammatory cytokines in the liver, WAT, or the circulation. As high-fat feeding would be expected to induce the secretion of liver-derived sDPP4 and augment WAT macrophage inflammation (Ghorpade et al., 2018) , our data using multiple animal models reveal an unanticipated dissociation between absence or reduction of circulating sDPP4, the cellular source of sDPP4, and the extent of systemic and tissue inflammation in different lines of HFD-fed mice.
Even more surprising was the finding that selective DPP-4 inhibition with MK-0626, a clinical backup candidate for sitagliptin (Edmondson et al., 2006; Mulvihill et al., 2016) , was associated with marked induction of circulating levels of sDPP4. Notably, we reproduced this observation in multiple different cohorts of mice, on different diets, treated for various time periods (2-14 weeks) ( Figure 7) . Moreover, we demonstrated that treatment of mice with either sitagliptin or linagliptin, two widely used clinically approved DPP-4 inhibitors, also rapidly increased circulating levels of sDPP4. Furthermore, our experiments using mouse genetics demonstrated that Dpp4 expression within Tie2 + hematopoietic or endothelial cells is required for the DPP-4 inhibitor-mediated induction of circulating sDPP4. The putative importance of hematopoietic cells for generation of sDPP4 identified here is also consistent with results of bone marrow transplantation experiments in DPP-4-deficient rats and mice (Casrouge et al., 2018; Wang et al., 2014) . Surprisingly, we were unable to find previous reports describing upregulation of sDPP4 levels in the context of catalytic DPP-4 inhibition in animals or humans. Intriguingly, sitagliptin rapidly and dose-dependently induced expression of the DPP4 gene in SerpinB3-expressing human liver cell lines ex vivo (Fasolato et al., 2018) , consistent with the existence of an autoregulatory feedback loop linking reduction of DPP-4 activity to augmentation of DPP-4 production. Indeed, enzymatic inhibition of angiotensin-converting enzyme activity or neutral peptidase activity also induced the expression of the cognate enzymes (Helin et al., 1994) , in keeping with a model linking inhibition of enzyme activity with upregulation of enzyme biosynthesis.
Collectively, several reports support a direct pro-inflammatory role for sDPP4 in cell types such as lymphocytes, macrophages, and smooth muscle cells (Ghorpade et al., 2018; Ohnuma et al., 2007; Wronkowitz et al., 2014; Zhong et al., 2013; Zhuge et al., 2016) . Nevertheless, our current findings dissociate the circulating levels of endogenous sDPP4 and the extent of systemic and WAT inflammation in multiple different mouse models (Figure S7) . Furthermore, the demonstration that selective inhibition of DPP-4 enzymatic activity leads to robust induction of circulating sDPP4 without concomitant changes in inflammation raises further questions about the experimental and pathophysiological context linking changes in levels of sDPP4 to pro-inflammatory pathways. Intriguingly, DPP-4 inhibitors are widely used in conjunction with metformin, an agent associated with (1) reduced levels of circulating sDPP4 (Ahmed et al., 2015; Zhong et al., 2015) and (2) decreased numbers of major cardiovascular events, relative to DPP-4 inhibitors alone, in cardiovascular outcome studies (Crowley et al., 2017) . Given the widespread use of DPP-4 inhibitors in human subjects with diabetes and inflammatory co-morbidities, including cardiovascular disease (Mulvihill and Drucker, 2014) , it seems prudent to further elucidate the circumstances and co-factors linking changes in soluble and tissue DPP-4 with ambient DPP-4 activity, and sDPP4-mediated regulation of inflammation.
Limitations of Study
An important limitation of these experiments is the exclusive analysis of mouse models. Hence we are as yet unable to determine whether sDPP4 correlates with inflammation or is upregulated by catalytic DPP-4 inhibition in humans. Furthermore, the majority of our mice were normoglycemic or modestly dysglycemic, analyzed following RC or HFD feeding conditions. Hence, whether the inflammatory activity of sDPP4 varies in animal models with different genetic or acquired forms of diabetes, and insulin resistance, requires further analysis. Finally, we observed robust upregulation of sDPP4 in the context of sustained robust inhibition of DPP-4 enzyme activity. In contrast, humans administered DPP-4 inhibitors for the treatment of diabetes are likely to experience less sustained inhibition of DPP-4 enzyme activity over a 24-hr period. Taken together, our findings highlight the putative translational importance of understanding the link between DPP-4 enzyme inhibition, and the circulating levels of pro-inflammatory sDPP4 in human subjects.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (CD) or an HFHC diet for 10 weeks, followed by an additional 2 or 14 weeks on HFHC diet ± DPP4i (I and J) (n = 9-10/group), or in 20-week-old WT mice fed an RC diet and then directly switched to either HFHC or HFHC diet + MK-0626 for 1, 2, 3, and 4 weeks (K and L) (n = 5/group), or in WT mice fed HFD for 12 weeks and administered a one-time injection of streptozotocin (90 mg/kg i.p.) and fed HFD + MK-0626 (18 mg/kg food) for an additional 15 weeks and having undergone sham or transaortic constriction (TAC) surgery for initiation of pressure overload-induced heart failure (M) (Mulvihill et al., 2016) (n = 5-12/group). (N and O) Plasma DPP-4 activity (N) and plasma sDPP-4 protein level (O) in 12-week-old WT mice with free access to water containing either 18 mg/L MK-0626 (MK, red), 4 g/L sitagliptin (Sita, green) or 37.5 mg/L linagliptin (Lina, blue), or no drug (water, black) for 3 or 7 days (n = 10-20/group). Data are presented as the means ± SEM. *p % 0.05, **p % 0.01, ***p % 0.001, ****p % 0.0001 using t test (A-E) or one-way ANOVA (F-O). See also Figure S7 .
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this article online at https://doi.org/10.1016/j.cmet.2018.10.001.
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The authors would like to acknowledge the Pathology Department at the Center for Modeling Human Disease (CMHD) and the Microscopy Core at the . All mice were given free access to food and water, unless otherwise noted. Whole body Dpp4 -/mice were from a colony described previously (Marguet et al., 2000; Sauve et al., 2010) . db/db and db/ + mice were purchased from Jackson laboratories (#000697). Flox Dpp4 Flox/Flox mice were obtained from Merck Research Laboratories as previously described (Mulvihill et al., 2017) . B6;FVB-Tg(Adipoq-cre)1Evdr/J mice (Adipoq-Cre, Cat # 010803) and B6.Cg-Tg(Tek-cre) 1Ywa/J mice (Tie2-Cre, Cat # 008863) were obtained from Jackson Laboratories (Bar Harbor MI). Germline deletion was prevented by restricting Cre expression to male breeders. To control for gene dosage, breeders were heterozygous for the Cre gene. Intercrossing Cre-positive and Cre-negative Dpp4 loxP heterozygotes from these 2 lines resulted in 6 genotypes: wildtype mice with no Cre (WT), mice homozygous for the LoxP Dpp4 gene (Dpp4 Flox/Flox ), wildtype mice expressing Cre recombinase (Adipoq-Cre or Tie2-Cre) and Dpp4 Flox/Flox mice expressing Cre recombinase (Dpp4 Adipo-/and Dpp4 EC-/-). Whenever possible, we carried out experiments in all groups of mice. However, due to lack of phenotypic differences in the control lines (Mulvihill et al., 2017) , data are presented as a single control group of pooled Adipoq-Cre and Dpp4 Flox/Flox mice. All mice were born at the expected Mendelian ratios and appeared healthy. All experiments used age-and sex-matched littermates. For metabolic tests in adult mice, RC diet experiments were performed in 8-12 week old mice, and HFD experiments, in 16-20 week old mice fed the 45% HFD for 8-12 weeks. For experiments in old Dpp4 Adipo-/mice, 1-year-old Adipoq-cre and Dpp4 Adipo-/mice were put on HFHC and oGTT and ITT were performed after 2 and 3 weeks of HFHC feeding, respectively. Mice were sacrificed and adipocyte and SVF fractions were isolated after 4 weeks on the diet to measure inflammation and assess DPP4 gene knockdown.
To generate Dpp4 Hep-/mice, Dpp4 Flox/Flox adult mice were i.v. injected with 1.5x10 11 GC per mouse (in 100ml) of AAV8.TBG. pi.egfp.wpre.bgh (AAV-GFP; control virus) or AAV8.TBG.PI.CRE.rBG (AAV-Cre; a Thyroxin Binding globulin promoter driving cre expression that specifically targets hepatocytes, and not Kupffer cells or endothelial cells). Both AAV constructs were obtained from the University of Pennsylvania Vector Core Lab. Most of the experiments were also performed in mice injected with PBS, and as no difference was observed between the GFP and the PBS group, GFP alone was used as a control. For RC diet experiments, female and male mice were injected when 8-12 weeks old. For HFHC experiments, mice were put on diet for 10 weeks, starting when they were 8-12 weeks old, and then injected with virus. Metabolic analyses were performed 1, 2 and 3 weeks after injection and mice were sacrificed 4 weeks post injection.
Chronic inhibition of DPP-4 enzymatic activity was achieved by administering MK-0626 (((2S,3S)-1-(3,3-difluropyrrolidin-1-yl)-4-(dimethylamino)-1,4-dioxo-3-(4-[1,2,4]triazolo[1,5-A]pyridin-6-ylphenyl)butan-2-aminium chloride) (Edmondson et al., 2006) in the diet (3 mg/kg body weight Merck Laboratories, Rahway, NJ) (Mulvihill et al., 2016) . MK-0626 was administered to control mice (Adipoq-cre mice) fed a HFHC diet for 10 weeks. Mice underwent blood collection and oral glucose tolerance testing 2 weeks later and were sacrificed 4 weeks after the start of MK-0626 treatment.
Plasma DPP-4 activity and sDPP4 protein levels in response to DPP4 inhibition, was assessed in 5 independent experiments: 1) WT mice fed CD or HFHC diet for 10 weeks, followed by an additional 2-or 14-weeks on the same diet ± MK-0626 (18mg/kg food); 2) 20 week-old WT mice fed RC diet and then switched to either HFHC or HFHC + MK-0626 (18mg/kg food) diet for 1, 2, 3 and 4 weeks; 3) 1-year-old STZ-treated (90mg/kg), dysglycemic WT mice fed a HFD ± MK-0626 (18mg/kg food) and following sham or Transaortic Constriction (TAC) surgery (as described in Mulvihill et al., 2016) ; 4) MK-0626 (18mg/L water;2-2.5mg/Kg BW/day); or sitagliptin (4g/L dissolved water; 120-140mg/kg BW/day for the first 24h, then 350-400mg/kg BW/day) or linagliptin (37.5mg/L dissolved in water; 5-5.5mg/kg BW/day) added into the drinking water of 8-12 week-old WT mice for 3 or 7 days. Doses of DPP4 inhibitors were based on previous published studies and pilot studies in our laboratory (Mulvihill et al., 2016, MK-0626; Kyle et al., 2011, Sitagliptin; Kern et al., 2012, Linagliptin) . Water bottles were added 24h before the day of the experiment to acclimate the mice. Fresh drug was added every 72 hours. Mice were bled before, as well as 3 and 7 days after starting the treatment. 5) Before or after 3, 7, 14 and 35 days of treatment with MK-0626 (18mg/kg food in HFHC diet) in a) Dpp4 Hep-/and Dpp4 Hep+/+ controls (AAV-GFP injected), b) Dpp4 EC-/and Tie2-cre controls, c) Dpp4 Adipo-/and Adiponectin-cre controls, and d) Dpp4 Gut-/and Villin-cre controls (as described in Mulvihill et al., 2016) .
The data presented in this research article were from experiments performed in male mice. However, the main experiments supporting our conclusions (plasma DPP4 activity in all mouse models, body weight, insulin and oral Glucose Tolerance Tests, incretin and insulin levels in Dpp4 Hep-/vs. their respective controls) were performed in both males and females and the results showed no influence of gender on any of those parameters.
Cell Culture: 3T3-L1 Cells 3T3-L1 fibroblasts were grown at 7% CO 2 and 37C in 35 mm dishes in DMEM, 25 mM glucose, 10% calf serum, and induced to differentiate to adipocytes as previously described (Gual et al., 2003) . Briefly, 2 days after reaching confluence, the media was changed to DMEM, 25 mM glucose, 10% fetal calf serum (FCS), supplemented with isobutylmethylxanthine (0.25 mM), dexamethasone (0.25 mM), insulin (5 mg/ml), and pioglitazone (10 mM). The media was removed after 2 days and replaced with DMEM, 25 mM glucose, 10% FCS, supplemented with insulin (5 mg/ml) and pioglitazone (10 mM) for 2 days. The cells were then fed every 2 days with DMEM, 25 mM glucose, 10% FCS. 3T3-L1 cells were harvested at D0, D2, D4, D6, D8 and D10 post-induction into 1ml Trizol for RNA isolation. Dulbecco's modified Eagle's medium (DMEM), fetal calf serum, and calf serum were obtained from Life Technologies (St Louis, MO, USA). Insulin was from Lilly (Paris, France). All other chemical reagents were purchased from Sigma (St Louis, MO, USA).
METHOD DETAILS
Glucose and Insulin Tolerance Tests After a 5 hour fast, mice were orally administered water or sitagliptin (Merck Laboratories) at 10 mg/kg (systemic inhibition); followed 30 minutes later by a gavage of 2 g/kg glucose in PBS. For insulin tolerance tests (ITT), human insulin (Humalog, Lilly) was injected (i.p.) at a dose of 0.5 U/kg or 1U/kg. Blood for glucose measurements (Contour glucometer, Bayer Healthcare, Toronto, Canada) was obtained from the tail vein before and at 15, 30, 45, 60, 90 and 120 min post-glucose gavage.
Experiments with Exendin-4
Wildtype mice were put on HFD for 10 to 20 weeks (5 in each group), and then i.p. injected twice a day with 5 nmol/kg of exendin-4 (10am and 6pm) for 7 days. Blood glucose was recorded and mice were bled at the indicated times for measurement of plasma DPP-4 activity.
Blood and Tissue Collection
All blood samples were collected in heparin-coated capillary microvette tubes and plasma isolated after centrifugation (13,000rpm 5min 4 C). During oral glucose tolerance tests, blood was taken via the tail vein before gavage and 15 min after glucose gavage. For terminal studies, mice were sacrificed by CO 2 inhalation and blood was obtained by cardiac puncture.
For measurement of plasma active GLP-1 (Mesoscale), active GIP (Crystal Chem), and insulin (ultrasensitive insulin ELISA, Alpco Diagnostics), blood was mixed with 10% TED (vol/vol) (5,000 KIU/ml Trasylol, 1.2 mg/ml EDTA and 0.1 nmol/l Diprotin A) and plasma stored at -80 C until further analysis.
To measure the protein levels of pro-inflammatory cytokines and DPP-4 activity, 40-70 mg of liver tissue or 200-350 mg of WAT tissue were homogenized in 500 ml of lysis buffer (50 mM Tris HCl (pH 8 at 4 C), 1 mM EDTA, 10% glycerol (wt/vol), 0.02% Brij-35 (wt/vol)). Lysis buffer was supplemented with 1 mM dithiothreitol and protease inhibitor for cytokine assay only. Tissue and plasma (containing 10% TED) levels of cytokines were measured using the MSD V-PLEX Mouse Proinflammatory Panel assay kit (Mesoscale). Cytokine concentrations in tissue were normalized to total protein amount measured by Bradford Assay. DPP-4 activity was assessed using a fluorometric assay (substrate: 10 mM H-Gly-Pro-AMC HBr (Bachem #I-1225), standard: AMC (Bachem #Q-1025)) using 10ml of plasma (no TED) or 25ml of tissue or cell homogenate. DPP-4 activity was normalized to total tissue weight or protein amount. DPP4 protein level was measured using 100 ml of plasma (diluted 1/120) from 5-hour fasted mice using the mouse DPPIV/CD26 DuoSet ELISA kit (DY954; R&D System) following the manufacturer's instructions. Throughout the manuscript, the term ''soluble DPP4'' (sDPP4) is used to describe the protein level of DPP4 measured in the circulation (plasma).
Body Weight and Body Composition
Body weight was measured once a week after a 5 hour fast. Body composition was measured by EchoMRI quantitative nuclear magnetic resonance (NMR) system (Echo Medical Systems, Houston, TX).
Mature Adipocytes and SVF Isolation
Adipose tissue depots (inguinal, epididymal, retroperitoneal white adipose tissue (WAT) and interscapular brown adipose tissue (BAT)) were isolated from RC-, HFD-, or HFHC diet-fed C56BL/6J mice from the Toronto Centre for Phenogenomics in house colony. Tissues were finely minced on ice, and then digested for 30-50 min in 1mg/ml collagenase in HBSS containing 3% BSA and 5U/ml DNase I at 37 C with gentle agitation. Digestion was stopped with PBS containing 10% FBS and the solution was filtered (500mm). Mature adipocytes and SVF fractions were then separated and washed by several successive low speed centrifugations (1000-2000 rpm). The lipid-containing adipocytes floated to the top, whereas the pellet contained the SVF fraction. After washing, cells were either suspended in 1-2 ml Trizol for RNA isolation (and then stored at -80 C) or in homogenization buffer (50 mM Tris HCl (pH 8 at 4 C), 1 mM EDTA, 10% glycerol (wt/vol), 0.02% Brij-35 (wt/vol)) to measure DPP4 activity. For assessment of DPP-4 enzymatic activity, cells were washed twice with PBS to eliminate traces of BSA/FBS. Protein levels were measured by Bradford protein assay. DPP-4 activity was normalized to total protein amount. 4 cycles of hepatocyte depletion, the NPC pellet was enriched in macrophages and endothelial cell markers and depleted of albuminexpressing hepatocytes ( Figure S4C ) and was collected for further analysis.
Genomic DNA Isolation and Gene Expression
Genomic DNA was isolated from mouse tissue using 50mM NaOH, heating for 10 min at 95 C and then adding a 10% volume of 1M Tris pH8. Total RNA was extracted from tissues using Tri Reagent (Molecular Research Center, Cincinnati, OH). cDNA was synthesized from DNase I-treated (Thermo Fisher Scientific, Markham, ON) total RNA (0.5-3mg) using random hexamers and Superscript III (Thermo Fisher Scientific, Markham, ON). Real-time PCR was carried out using a QuantStudio System and TaqMan Gene Expression Assays (Thermo Fisher Scientific, Markham, ON).
Primer probe sets were manufactured by Taqman Assays-on-Demand (Applied Biosystems). The standard curve method was used to determine mRNA concentrations, and each gene was normalized to cyclophilin (Ppia) or TATA box binding protein (Tbp) expression, unless otherwise noted.
Detection of Full Length Mouse Dpp4 mRNA
Total RNA was isolated using TRIzol reagent (Sigma). 2 mg total RNA was reversed transcribed at 50 C for 60 min using Superscript III reverse transcriptase and random hexamers (Sigma). The mouse Dpp4 gene was amplified by PCR using primer pairs 5'-CAT CAT CAC CGT GCC AAT AG -3' and 5'-TAT CAT CTG CCG TTC CAT GA -3'. Amplification of mouse Dpp4 cDNA resulted in generation of an approximately 1 kb PCR product. After gel electrophoresis and transfer to nylon membranes, blots were hybridized with a 32 P-labeled mouse (5'-CCA CAC AAA TGT GAA GTC CC -3') Dpp4 oligonucleotide probe overnight. After washing, blots were visualized using a Storm 860 Phosphor Screen and analyzed with Quantity One imaging software (Bio-Rad).
Immunostaining
Immunostaining was performed by the Pathology core at The Centre for Phenogenomics. Briefly, sections were de-paraffinised and rehydrated. Sections were incubated in methanol + 0.3% H 2 O 2 to block endogenous peroxidase activity. Antigen retrieval in TBS containing Proteinase K was performed. Dako protein block was used to block non-specific background staining. Primary antibodies were DPP-4 (R&D Biosytem, AF954) or Mouse F4/80 (Abcam, Cat # ab16911). A biotinylated Rabbit secondary antibody was applied (Vector labs, Cat # BA-4001) followed by Vectastain Elite ABC-HRP peroxidase (Vector laboratories, Cat # PK-6100). Positive staining was visualized using DAB/Plus substrate (Abcam, Cat # ab103723) following manufacturer's instructions. Sections were counterstained with Mayer's Hematoxylin (Sigma-Aldrich, Cat # MHS32-1L). Digital images were obtained using an Olympus VS120 slide scanner and images were exported using NDP View 2.7.25 software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Results are expressed as the mean ± SEM. Statistical comparisons were made by ANOVA followed by a Tukey post-hoc, a 2-way ANOVA followed by a Sidak post-hoc, or by Student t-test (when only 2 conditions) using GraphPad Prism 7. No methods were used to determine whether the data met assumptions of the statistical approach. Statistical parameters can be found in the figure legends. Statistically significant differences are indicated as * P%0.05, ** P%0.01, *** P%0.001, and **** P%0.0001. A: Recombination of genomic DNA (gDNA) measured by standard PCR in liver and inguinal white adipose tissue (iWAT) isolated from WT, Dpp4 Flox (Flox), Adiponectin-Cre (Cre), and Dpp4 Adipo-/-(Adipo-/-) 20 week old male mice under chow diet conditions. B: gDNA recombination detected by standard PCR in adipocytes (A) and stromal vascular fraction (S) from iWAT, epididymal white adipose tissue (eWAT), and retroperitoneal white adipose tissue (rWAT) isolated from Adiponectin-Cre Dpp4 +/+ (+) and Dpp4 Adipo-/-(-) 20-week-old male mice under chow diet-fed conditions. C-E: Body weight (C), fat mass measured by Echo-MRI (D) and by dissection after sacrifice (E), in Dpp4 Adipo+/+ (pooled Adiponectin-Cre and Dpp4 flox) and Dpp4 Adipo-/mice fed RC or a HFD. F-I: Plasma DPP4 activity and protein levels (soluble DPP4, sDPP4) (F), Fasting blood glucose (G), glucose excursion and AUC following an oral glucose challenge (H), and plasma insulin and active GLP-1 levels at baseline (0) and 15 min after oral glucose administration (2g/kg) (I) in Dpp4 Adipo+/+ and Dpp4 Adipo-/mice fed RC or a HFD (n=8-30/group). J-L: Glucose excursion, plasma insulin, active plasma GLP-1 concentrations after oral gavage of glucose (2g/kg, 5 hr fast) in Dpp4 Adipo+/+ and Dpp4 Adipo-/mice fed a RC diet (J,K) or a HFD (L,M) +/-acute oral administration of sitagliptin (10mg/kg) 30 minutes prior to glucose gavage (n=14-28/group). Data are presented as the mean ± SEM. * P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 0.0001. 
